Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
|Slideshows|September 14, 2016
ADHD Research Update: September 2016
Author(s)Mark L. Fuerst
Three new studies in children with ADHD reveal an association with seizures, the benefits of after-school exercise, and brain changes linked to treatment.
Advertisement
References:
1. Bertelsen EN, Larsen JT, Petersen L, et al.
2. Bustamante EE, Davis CL, Frazier SL, et al.
3. Schrantee A, Tamminga HGH, Bouziane C, et al.
Advertisement
Related to this article
Learn how to prevent and spot tardive dyskinesia from antipsychotics, track key risk factors, and treat symptoms with VMAT2 inhibitors.
Learn how the inhibition constant and 5-HT2A binding explain LSD effects—and why potent atypical antipsychotics may rapidly end a bad trip.
FDA hearing spotlights debates over psychedelic therapy: who administers, how to prove efficacy, and how to track safety as approvals near.
New US adult ADHD guidance nears publication, promising clearer diagnosis, comorbidity screening, and clinician training to curb misdiagnosis.
FDA clears Simtriyo, first NDSRI stimulant for ADHD ages 6 and older, as millions return to school—see what this means for treatment.
Experts dissect 10 common antidepressant myths, separating evidence from fear on efficacy, addiction, suicide risk, withdrawal, and safe tapering.
Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.
Advertisement
Advertisement
Trending on Psychiatric Times
1
New Adult ADHD Guidelines: What Resources Are Coming Soon
2
The Silence Between the Questions: Reflections on Adolescent Suicide Risk When Intent Is Unclear
3
Centanafadine For Comorbid ADHD and Anxiety: Talking New Data With John Kraus, MD, PhD
4
FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval
5